Primovist, Eovist: What to expect?

Beers, Bernard E. Van; Pastor, Catherine M.; Hussain, Hero K.

doi:10.1016/j.jhep.2012.01.031

Cited by 359 publications

(350 citation statements)

References 85 publications

Supporting

Mentioning

338

Contrasting

Unclassified

Order By: Relevance

“…This contrast enables detection of even very small hepatic metastases or hepatocellular carcinoma as hypointense lesions in bright liver tissue. 2,[8][9][10][11][12] The use of hepatobiliary-phase images for the evaluation of hepatic function has also been suggested. 13,14 The approved package insert dose of gadoxetic acid, 0.025 mmol/kg, yields a quarter of the dose of gadolinium of traditional formulation agents, including gadopentetate dimeglumine, gadoteridol, gadodiamide, gadoversetamide, and gadobenate dimeglumine.…”

Section: Introductionmentioning

confidence: 99%

Intraindividual Crossover Comparison of Gadoxetic Acid Dose for Liver MRI in Normal Volunteers

Bannas

Hernando

Rahimi

et al. 2016

MRMS

View full text Add to dashboard Cite

Purpose: We performed a quantitative intraindividual comparison of the performance of 0.025-and 0.05-mmol/kg doses for gadoxetic acid-enhanced liver magnetic resonance (MR) imaging.Materials and Methods: Eleven healthy volunteers underwent liver MR imaging twice, once with a 0.025-and once with a 0.05-mmol/kg dose of gadoxetic acid. MR spectroscopy and 3-dimensional gradient-echo T 1 -weighted images (3D-GRE) were obtained before and 3, 10, and 20 min after injection of the contrast medium to measure T 1 and T 2 values and signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) performance. During the dynamic phase, highly time-resolved 3D-GRE was used to estimate the relative CNR (CNR rel ) of the hepatic artery and portal vein (PV) to the liver. We used paired t-tests to compare the results of different doses.Results: During the hepatobiliary phase, we observed shorter T 1 values and higher SNRs of the liver (P < 0.001) and higher liver-to-PV and liver-to-muscle CNRs (P < 0.002) using 0.05 mmol/kg compared to 0.025 mmol/kg. Increasing the dose to 0.05 mmol/kg yielded a greater T 1 -shortening effect at 10 min delay even compared with 0.025 mmol/kg at 20 min (P < 0.001). During the dynamic phase, the peak CNR rel for the hepatic artery and portal vein were higher using 0.05 mmol/kg (P = 0.007 to 0.035).Conclusion: Use of gadoxetic acid at a dose of 0.05 mmol/kg leads to significantly higher SNR and CNR performance than with 0.025 mmol/kg. Quantitatively, a 10-min delay may be feasible for hepatobiliary-phase imaging when using 0.05 mmol/kg of gadoxetic acid.

show abstract

Section: Introductionmentioning

confidence: 99%

Intraindividual Crossover Comparison of Gadoxetic Acid Dose for Liver MRI in Normal Volunteers

Bannas

Hernando

Rahimi

et al. 2016

MRMS

View full text Add to dashboard Cite

show abstract

“…Due to its liposoluble characteristics, gadoxetic acid enters into hepatocytes through the cell membrane transporters type OATP1B1 and OATP1B3, and exits through the canalicular ATP-dependent protein related to multidrug resistance (MRP2) 4 . There are also proteins MRP3 and MRP4, allowing efflux of contrast medium back to the liver sinusoids.…”

Section: Introduction Introduction Introduction Introduction Introducmentioning

confidence: 99%

“…In the evaluation of liver metastases (Figure 2), the most interesting feature of gadoxetic acid is the ability to detect more lesions in the hepatobiliary phase 4 , with dimensions as small as 0.2 cm, particularly when employing high resolution three-dimensional images in more recent generations devices. In one of the cases evaluated, the patient presented had a prior routine examination suggesting possible surgical indication and the MRI with contrast hepatic-specific identified three additional lesions, which changed the treatment plan.…”

Section: Introduction Introduction Introduction Introduction Introducmentioning

confidence: 99%

Ressonância magnética do fígado com contraste hepato-específico: experiência clínica inicial no Brasil

Bittencourt

Hausmann

Gasparetto

et al. 2013

Rev. Col. Bras. Cir.

View full text Add to dashboard Cite

ABSTRACT ABSTRACT ABSTRACTThe authors report the initial clinical experience, in a private service in Brazil, with the use of gadoxetic acid, a hepatic-specific magnetic resonance imaging (MRI) contrast medium. This substance, recently approved for commercial use in the country, can be specifically captured by hepatocytes, reaching a peak concentration in about 10-20 minutes after intravenous injection. The main indications for its use in MRI include: diagnosis of hepatocellular carcinoma, detection and treatment planning of liver metastases and the differentiation between focal nodular hyperplasia and hepatocellular adenoma.

show abstract

“…The liver-specific contrast agent Gd-EOB-DTPA is suitable for detecting and characterizing liver lesions particularly by combining vascular phases with an additional hepatobiliary phase [21 -24]. The hepatobiliary phase of Gd-EOB-DTPA is made possible by the selective uptake of membrane-bound organic anion transporters (OATP1 B1 / B3) [1, 25,26]. In addition to biliary elimination [11,27], Gd-EOB-DTPA is also eliminated with the help of glomerular filtration in the kidneys [4].…”

mentioning

confidence: 99%

Multivariable Analysis of Clinical Influence Factors on Liver Enhancement of Gd-EOB-DTPA-Enhanced 3T MRI

Verloh

Haimerl

Zeman

et al. 2014

Fortschr Röntgenstr

View full text Add to dashboard Cite

!Purpose: The purpose of this study was to identify clinical factors influencing Gd-EOB-DTPA liver uptake in patients with healthy liver parenchyma. Materials and Methods: A total of 124 patients underwent contrast-enhanced MRI with a hepatocyte-specific contrast agent at 3 T. T1-weighted volume interpolated breath-hold examination (VIBE) sequences with fat suppression were acquired before and 20 minutes after contrast injection. The relative enhancement (RE) between plain and contrast-enhanced signal intensity was calculated. Simple and multiple linear regression analyses were performed to evaluate clinical factors influencing the relative enhancement. Patients were subdivided into three groups according to their relative liver enhancement (HRE, RE ≥ 100 %; MRE, 100 % > RE > 50 %; NRE, RE ≤ 50 %) and were analyzed according to the relevant risk factors. Results: Simple regression analyses revealed patient age, transaminases (AST, ALT, GGT), liver, spleen and delta-liver volume (the difference between the volumetrically measured liver volume and the estimated liver volume based on body weight) as significant factors influencing relative enhancement. In the multiple analysis the transaminase AST, spleen and delta liver volume remained significant factors influencing relative enhancement. Delta liver volume showed a significant difference between all analyzed groups. Conclusion: Liver enhancement in the hepatobiliary phase depends on a variety of factors. Body weight-adapted administration of Gd-EOB-DTPA may lead to inadequate liver enhancement after 20 minutes especially when the actual liver volume differs from the expected volume.

show abstract

Primovist, Eovist: What to expect?

Cited by 359 publications

References 85 publications

Intraindividual Crossover Comparison of Gadoxetic Acid Dose for Liver MRI in Normal Volunteers

Intraindividual Crossover Comparison of Gadoxetic Acid Dose for Liver MRI in Normal Volunteers

Ressonância magnética do fígado com contraste hepato-específico: experiência clínica inicial no Brasil

Multivariable Analysis of Clinical Influence Factors on Liver Enhancement of Gd-EOB-DTPA-Enhanced 3T MRI

Contact Info

Product

Resources

About